Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MEK inhibition prevents human skin graft rejection by promoting CD8+TCF1+ T cells over CD8 effector differentiated T cells.

ABSTRACT: While graft loss remains primarily attributed to rejection, the adverse effects of immunosuppressive therapies significantly contribute to patient morbidity and mortality. Therefore, it is imperative to develop treatments that both prevent alloimmune damage to the transplant and are well tolerated. MEK inhibition has recently been showed to be effective in controlling the alloimmune response in experimental mouse graft-versus-host disease, without abrogating anti-tumor nor anti-viral immunity. Here, we demonstrate that pharmacological MEK inhibition delays human skin graft rejection by human T cells in a preclinical humanized mouse model. Although similar graft infiltration was observed between treated and untreated animals, human epidermal cells were protected by the treatment. Single cell RNAseq analysis of the spleen immune cells revealed that MEK inhibition treatment inhibits CD8 T cell development to an effector phenotype and promotes the accumulation of CD8+TCF1+ stem-like cells. Furthermore, analysis of the CD4 cells showed that MEK inhibition improved CD4 T cell recovery by preserving IL7R expression on CD4 T cells and favored CD4 T cells engagement in the Th1 lineage rather than the Tfh lineage. These findings suggest that MEK inhibition could be an innovative approach to combining allogeneic immune response control and tissue protection after transplantation.

ORGANISM(S): Homo sapiens

PROVIDER: GSE266482 | GEO | 2025/05/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

MEK inhibition prevents human skin graft rejection by promoting CD8+TCF1+ T cells over CD8 effector differentiated T cells.

Project description:MEK inhibition prevents human skin graft rejection by promoting CD8+TCF1+ T cells over CD8 effector differentiated T cells.

| PRJNA1107267 | ENA

Analysis of graft-infiltrating CD8+ T cell profile after CD3 antibody therapy

Project description:We performed a global gene expression analysis comparing intragraft tolerant CD8+ T cells from CD3 antibody-treated mice showing permanent islet graft survival to intra-graft effector CD8+ T cells isolated from untreated mice showing acute rejection of islet allografts. The objective was to emphasize the anergic profile of CD8+ T cells residing within the pancreatic islet allograft of mice rendered tolerant following CD3 antibody therapy.

2017-02-10 | GSE68208 | GEO

Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models

Project description:Solid organ transplant represents a potentially lifesaving procedure for patients suffering from end-stage heart, lung, liver, and kidney failure. However, rejection remains a significant source of morbidity and immunosuppressive medications have significant toxicities. Janus kinase (JAK) inhibitors are effective immunosuppressants in autoimmune diseases and graft versus host disease after allogeneic hematopoietic cell transplantation. Here we examine the role of JAK inhibition in preclinical fully major histocompatibility mismatched skin and heart allograft models. Baricitinib combined with cyclosporine A (CsA) preserved fully major histocompatibility mismatched skin grafts for the entirety of a 111-day experimental period. In baricitinib plus CsA treated mice, circulating CD4+T-bet+ T cells, CD8+T-bet+ T cells, and CD4+FOXP3+ regulatory T cells were reduced. Single cell RNA sequencing revealed a unique expression profile in immune cells in the skin of baricitinib plus CsA treated mice, including decreased inflammatory neutrophils and increased CCR2- macrophages. In a fully major histocompatibility mismatched mismatched heart allograft model, baricitinib plus CsA prevented graft rejection for the entire 28-day treatment period compared with 9 days in controls. Our findings establish that the combination of baricitinib and CsA prevents rejection in allogeneic skin and heart graft models and supports the study of JAK inhibitors in human solid organ transplantation.

2024-06-13 | GSE269828 | GEO

Effect of CD154:CD11b blockade on antigen-specific CD8 T cell response to murine Epstein-Barr virus infection

Project description:CD154 is a promising target for immunosuppression in transplantation, autoimmunity, and inflammatory diseases. We previously identified CD11b as a novel alternate receptor for CD154 during alloimmunity. However, the impact of specific CD154:CD11b blockade on immune responses to infection has not been well characterized. Here, we have shown that in contrast to its immunosuppressive effect on graft-specific CD8+ T cells, CD154:CD11b blockade unexpectedly improved both the quantity and quality of murine herpesvirus-68 (MHV)-specific CD8+ T cells as measured by an increase in tetramer-positive KLRG1loCD127hi memory precursor effector cells (MPECs). RNAseq of antigen-specific CD8+ T cells identified using an MHV68-specific MHC tetramer reveals specific pathways altered following cM7 treatment during MHV68 infection, including transcripts associated with T cell activation and survival. The differential effect of CD154:CD11b blockade on graft-vs. virus-specific CD8+ T cells was underpinned by differences in phospho-S6 downstream of mTORC1, however differential expression of key transcription factors Eomes and TCF-1 was dictated by the type of antigen stimulus. These data demonstrate that priming conditions play an important role in determining the outcome of immunotherapy and suggest that specific inhibition of CD154:CD11b interactions could be effective for suppressing alloimmune responses while maintaining protective immunity to minimize infectious complications following transplantation.

2025-04-11 | GSE293467 | GEO

Analysis of allospecific CD8 T cells in murine pregnancy or graft rejection

Project description:Analysis of allospecific CD8 T cells in murine pregnancy or graft rejection

| PRJNA892954 | ENA

Single cell RNA-seq profiling of CD8 T cells from elder adults

Project description:Single cell RNA-seq profiling of ~62k purified CD8+ T cell transcriptomes, from six healthy older adult donors using 10X genomics. Cells from each donor were separated based on their IL-7R protein expression (i.e. CD8+ IL7R+ and CD8+ IL7R- T cells).

| EGAS00001004255 | EGA

ASC controls T-bet-dependent CTL differentiation and defines transplant outcome independent of the inflammasome

Project description:The adaptor protein ASC is known to facilitate caspase-1 activation essential for innate host immunity via the formation of the inflammasome complex - a multi-protein structure responsible for processing IL-1beta and IL-18 to their active moieties. Here we demonstrate that ASC-deficient CD8+ T cells fail to induce graft-versus-host disease (GVHD) and have impaired capacity for graft rejection and graft-versus-leukemia (GVL) activity. These effects are the result of an inability to differentiate into fully cytolytic, granzyme B-expressing effector cells, with a developmental bias instead towards CD127+KLRG1- memory CD8+ T cells. These alterations in differentiation are inflammasome-independent, since GVHD lethality and CTL differentiation are not altered in recipients of caspase-1-deficient T cells. We demonstrate that ASC binds to T-bet in CD8+ T and in the absence of ASC, the binding of T-bet to the granzyme B promoter is impaired. Thus, the inhibition of ASC represents an attractive therapeutic target to manipulate transplant outcomes. Single colour, Illumina MouseRef-8 v2.0 Beadarrays.

2016-04-01 | E-GEOD-78755 | biostudies-arrayexpress

Transcriptome analysis of allospecific CD8 T cells in murine pregnancy or graft rejection

Project description:Transcriptome analysis of allospecific CD8 T cells in murine pregnancy or graft rejection

| PRJNA892958 | ENA

Epigenetic analysis of allospecific CD8 T cells in murine pregnancy or graft rejection

Project description:Epigenetic analysis of allospecific CD8 T cells in murine pregnancy or graft rejection

| PRJNA892087 | ENA

ImmPRes - PBMC derived CD4 and CD8 T cells

Project description:Dataset release from the Immunological Proteome Resource (ImmPRes). This dataset contains proteomic data from human CD4 and CD8 T cells isolated from PBMC. T-cells were activated with OKT3 antibody (anti CD3) and IL-2 for three days, then expanded in IL-2 until day 7. Cells were then sorted into live CD4 and CD8 T-cells.

2025-04-25 | PXD063325 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data